PressJuly 28, 2022 Hemplucid Becomes First Startup to Provide Psychedelic Therapy as Employee Healthcare Benefit
PressJuly 28, 2022 U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
PressJuly 28, 2022 Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
PressJuly 28, 2022 COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
PressJuly 27, 2022 Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth
PressJuly 26, 2022 COMPASS Pathways to announce second quarter 2022 financial results on August 4, 2022
PressJuly 26, 2022 Silo Wellness Organizes Jamaican Psilocybin Retreat Team and Advocates to Speak to Lane County Commissioners Regarding BM109 Optout Vote; Lane County Declines to Refer a Psilocybin Ban to Voters
PressJuly 25, 2022 FTO Files Requests for Reconsideration of U.S. Patent Trial and Appeal Board’s Decisions Concerning Petitions for Post Grant Review of Compass Patents
PressJuly 25, 2022 HAVN Life Announces Financing Commitment of C$9,000,000 through the issuance of Convertible Debentures and Warrants
PressJuly 22, 2022 Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines
PressJuly 22, 2022 Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio
PressJuly 21, 2022 Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
PressJuly 21, 2022 Delic 2021 Revenue Shows Strong Growth as Nation’s Largest Ketamine Clinic Chain, Continues Expansion of Mental Health Wellness Services
PressJuly 21, 2022 Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs
PressJuly 20, 2022 Delic Labs President and CSO Dr. Markus Roggen Named to Cannabis Scientist Power List for Third Consecutive Year
PressJuly 20, 2022 Clairvoyant Initiates First Site for Phase 2 Psilocybin Therapy Clinical Trial for Alcohol Use Disorder
